Disease Markers / 2016 / Article / Tab 2

Review Article

Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers

Table 2

Summary of available evidence for clinical applications of anti-Mullerian hormone.

Year Author Sample sizeStudy Outcomes

2013Fleming et al. [66] = 683 PCOSMeta-analysisAMH value of 4.7 ng/mL has the power to diagnose PCOS with
(i) 79.4% specificity and 82.8% sensitivity & AUC = 0.87 (95% CI 0.83–0.92)

2011Karkanaki et al. [2]Review Decreased AMH in
(i) Ageing, higher BMI, ovariectomy, chemo/radio therapy, GnRH administration, pregnancy, and oral contraceptive pills
Raised AMH in polycystic ovarian syndrome

2013 Lindhardt Johansen et al. [1]Review Diagnostic role of AMH in pediatric group includes the following:
(i) Determination of testicular tissue
(ii) Persistent Mullerian duct syndrome
(iii) Females with virilization and polycystic ovaries
(iv) Premature ovarian insufficiency
(v) Hypogonadotropic hypogonadism
(vi) Klinefelter syndrome
(vii) Granulosa cell tumor

2011Yates et al. [57]Case
= 423
RetrospectiveAMH tailor individualized ovarian stimulation significantly
(i) Increased embryo transfer (79–87%) and live birth rates (15.9–23.9%)
(ii) Decreased OHSS (6.9 to 2.3%) and failed fertilization (7.8 to 4.5%)
(iii) Reduced cost of fertility treatment by 29% per patient

2014Broer et al. [21]ReviewNovel indications for use of AMH for ovarian reserve testing in
(i) Small for gestational age
(ii) Type I diabetes mellitus
(iii) Autoimmune diseases like lupus erythematous
(iv) Ovarian surgery and uterine artery embolization for fibroids
(v) BRCA 1/2 mutation carriers

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.